The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000277.1(PAH):c.466G>C (p.Ala156Pro)

CA229562

102688 (ClinVar)

Gene: PAH
Condition: phenylketonuria
Inheritance Mode: Autosomal recessive inheritance
UUID: 1d56d7cf-cc3f-4605-a126-3d23c461b8c7
Approved on: 2023-12-30
Published on: 2023-12-30

HGVS expressions

NM_000277.1:c.466G>C
NM_000277.1(PAH):c.466G>C (p.Ala156Pro)
NC_000012.12:g.102866639C>G
CM000674.2:g.102866639C>G
NC_000012.11:g.103260417C>G
CM000674.1:g.103260417C>G
NC_000012.10:g.101784547C>G
NG_008690.1:g.55964G>C
NG_008690.2:g.96772G>C
ENST00000553106.6:c.466G>C
ENST00000307000.7:c.451G>C
ENST00000549111.5:n.562G>C
ENST00000551988.5:n.530+10823G>C
ENST00000553106.5:c.466G>C
NM_000277.2:c.466G>C
NM_001354304.1:c.466G>C
NM_000277.3:c.466G>C
NM_001354304.2:c.466G>C
NM_000277.3(PAH):c.466G>C (p.Ala156Pro)
More

Pathogenic

Met criteria codes 4
PP4_Moderate PM2_Supporting PS3_Supporting PM3_Very Strong

Evidence Links 3

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen PAH Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Phenylketonuria VCEP
The c.466G>C (p.Ala156Pro) variant in PAH has been reported in multiple individuals with PAH deficiency (BH4 deficiency excluded). (PMID: 26322415). This variant is absent in population databases. This variant was detected in trans with multiple pathogenic variants: p.H220P (PMID 26322415); c.611A>G (aka EX6-96A>G, PMID: 26600521); p.V5Sfs*33, p.R158W, p.R241C (2 patients), p.R261Q, p.R400T, p.T418P (PMID: 30050108). Functional studies show the PAH A156P mutant produces reduced protein (8.7% of wild type), with a residual enzyme activity of 10.4% (PMID 24327145). Computational evidence is conflicting. In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_very-strong, PM2_supporting, PP4_Moderate, PS3_supporting.
Met criteria codes
PP4_Moderate
p.[A156P] reported in one patient with classic PKU (Phe levels >20mg/dl). All patients fulfilled the diagnostic criteria of PKU, with a blood phenylalanine concentration >2mg/dl. BH4 deficiency was excluded by analysis of urinary pterins and dihydropteridine reductase activity in erythrocytes. PMID: 26322415

PM2_Supporting
Absent from controls in ExAC, 1000 Genomes, and ESP
PS3_Supporting
PMID 24327145: Relative quantity of PAH proteins for A156P 8.7%, the residual enzyme activity 10.4%

PM3_Very Strong
PMID 26322415: detected with p.[H220P] (not in ClinVar, LP by PAH VCEP) All mutations identified in patients were confirmed by analyzing parental DNA. When mutation loci were detected in patients, the same locus of the parental sample was amplified by PCR and analyzed by Sanger automated sequencing. Detected with c.611A>G (EX6-96A>G, P-6 submitters), parental analysis performed. PMID: 26600521 p.A156P/p.V5Sfs*33 (P-1), p.R158W (P-4)/p.A156P, p.R241C (P-8)/p.A156P (2 patients), p.R261Q (P-9)/p.A156P, p.A156P/p.R400T (P-1), p.A156P/p.T418P (P-1) The validation tests on parents were performed using Sanger sequencing. PMID: 30050108 Detected with p.R408Q parental analysis not reported PMID: 25894915

Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.